Soleno Therapeutics Inc [NASDAQ: SLNO] gained 10.98% or 5.6 points to close at $56.58 with a heavy trading volume of 4982383 shares.
It opened the trading session at $51.37, the shares rose to $56.8 and dropped to $51.25, the range by which the price of stock traded the whole day. The daily chart for SLNO points out that the company has recorded 15.99% gains over the past six months.
If we look at the average trading volume of 1.65M shares, SLNO reached to a volume of 4982383 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Soleno Therapeutics Inc [SLNO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLNO shares is $118.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLNO stock is a recommendation set at 1.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Soleno Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 20, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on June 23, 2025, representing the official price target for Soleno Therapeutics Inc stock. Previously, the target price had yet another raise to $74, while Stifel analysts kept a Buy rating on SLNO stock.
The Price to Book ratio for the last quarter was 11.88, with the Price to Cash per share for the same quarter was set at 5.40.
Trading performance analysis for SLNO stock
Soleno Therapeutics Inc [SLNO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.25. With this latest performance, SLNO shares dropped by -15.31% in over the last four-week period, additionally plugging by 15.99% over the last 6 months – not to mention a rise of 25.87% in the past year of trading.
Soleno Therapeutics Inc [SLNO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Soleno Therapeutics Inc [SLNO] shares currently have an operating margin of -570.55% and a Gross Margin at 93.25%. Soleno Therapeutics Inc’s Net Margin is presently recorded at -554.49%.
Soleno Therapeutics Inc (SLNO) Capital Structure & Debt Analysis
According to recent financial data for Soleno Therapeutics Inc. ( SLNO), the Return on Equity (ROE) stands at -69.53%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -56.90%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Soleno Therapeutics Inc’s Return on Invested Capital (ROIC) is -61.96%, showcasing its effectiveness in deploying capital for earnings.
Soleno Therapeutics Inc (SLNO) Efficiency & Liquidity Metrics
Based on Soleno Therapeutics Inc’s (SLNO) latest financial statements, the Debt-to-Equity Ratio is 0.22%, indicating its reliance on debt financing relative to shareholder equity.
Soleno Therapeutics Inc (SLNO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Soleno Therapeutics Inc. (SLNO) effectively leverages its workforce, generating an average of -$1968260.87 per employee. The company’s liquidity position is robust, with a Current Ratio of 15.13% and a Quick Ratio of 15.01%, indicating strong ability to cover short-term liabilities.
An analysis of Institutional ownership at Soleno Therapeutics Inc [SLNO]
There are presently around $110.35%, or 112.36%% of SLNO stock, in the hands of institutional investors. The top three institutional holders of SLNO stocks are: VIVO CAPITAL, LLC with ownership of 7.32 million shares, which is approximately 18.9401%. CARLYLE GROUP INC., holding 4.07 million shares of the stock with an approximate value of $$166.36 million in SLNO stocks shares; and CARLYLE GROUP INC., currently with $$137.14 million in SLNO stock with ownership which is approximately 8.6946%.
